Antibiotics in Patients With Acute Respiratory Tract Infection With Procalcitonin as Parameter
Primary Purpose
Respiratory Tract Infection
Status
Completed
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
laboratory value procalcitonin
Sponsored by
About this trial
This is an interventional treatment trial for Respiratory Tract Infection focused on measuring primary care, procalcitonin, antibiotic prescription
Eligibility Criteria
Inclusion Criteria:
- 18 years or older
- Informed consent
- Respiratory tract infection based on the clinical judgement of the primary care physician
Exclusion Criteria:
- Antibiotic pretreatment in previous 14 days
- Portal hypertension
- Major surgeries or multiple trauma which require hospitalization, in previous 4 weeks
- Autoimmune disease and systemic diseases (lupus erythematodes, wegener´s disease)
- Peritoneal dialysis
- Acute treated or recently operated medullary c-cell-carcinoma, SCLC, carcinoid
- Other inflammatory diseases (e.g. urinary tract infection, pyelonephritis, pancreatitis
Sites / Locations
- Medical School Hannover, Department Pneumology
Outcomes
Primary Outcome Measures
days with significant impairment due to acute respiratory tract infection
Secondary Outcome Measures
number of antibiotic prescriptions
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00688610
Brief Title
Antibiotics in Patients With Acute Respiratory Tract Infection With Procalcitonin as Parameter
Official Title
Antibiotics in Patients With Acute Respiratory Tract Infections in Primary Care in Consideration of Procalcitonin as Additive Parameter
Study Type
Interventional
2. Study Status
Record Verification Date
January 2009
Overall Recruitment Status
Completed
Study Start Date
November 2007 (undefined)
Primary Completion Date
June 2008 (Actual)
Study Completion Date
June 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Hannover Medical School
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Antibiotics in patients with acute respiratory tract infections in primary care in consideration of procalcitonin as additive parameter.
The purpose of this study is to compare the ordinary manner of antibiotic- prescription with the prescription in consideration of procalcitonin-value in patients with acute respiratory tract infections.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Tract Infection
Keywords
primary care, procalcitonin, antibiotic prescription
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
571 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Other
Intervention Name(s)
laboratory value procalcitonin
Intervention Description
A. attending physician includes patient with acute respiratory infection in study, indicates antibiotic prescription and collects procalcitonin-value. Waits for decision from laboratory either "change of decision" or "retention of decision". In case of "change decision": antibiotic is not recommended, patient shall not take antibiotic. In case of "retention of decision": patient may take the antibiotic.
B. attending physician includes patient with acute respiratory infection in study, indicates NO antibiotic and collects procalcitonin-value. Waits for decision from laboratory either "change of decision" or "retention of decision". In case of "change decision": antibiotic is recommended, patient has to be informed about. In case of "retention of decision": no change.
Primary Outcome Measure Information:
Title
days with significant impairment due to acute respiratory tract infection
Time Frame
14 to 28 days after infection
Secondary Outcome Measure Information:
Title
number of antibiotic prescriptions
Time Frame
28 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 years or older
Informed consent
Respiratory tract infection based on the clinical judgement of the primary care physician
Exclusion Criteria:
Antibiotic pretreatment in previous 14 days
Portal hypertension
Major surgeries or multiple trauma which require hospitalization, in previous 4 weeks
Autoimmune disease and systemic diseases (lupus erythematodes, wegener´s disease)
Peritoneal dialysis
Acute treated or recently operated medullary c-cell-carcinoma, SCLC, carcinoid
Other inflammatory diseases (e.g. urinary tract infection, pyelonephritis, pancreatitis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Olaf Burkhardt, Dr.
Organizational Affiliation
Medical School Hannover
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical School Hannover, Department Pneumology
City
Hannover
ZIP/Postal Code
30625
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
20185423
Citation
Burkhardt O, Ewig S, Haagen U, Giersdorf S, Hartmann O, Wegscheider K, Hummers-Pradier E, Welte T. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J. 2010 Sep;36(3):601-7. doi: 10.1183/09031936.00163309. Epub 2010 Feb 25.
Results Reference
derived
Learn more about this trial
Antibiotics in Patients With Acute Respiratory Tract Infection With Procalcitonin as Parameter
We'll reach out to this number within 24 hrs